Rice University's top innovation exec leaving for new role at UVA

moving on

Paul Cherukuri, Rice’s first vice president for innovation and chief innovation officer, will leave his post next month. Photo via Rice.edu

Paul Cherukuri, Rice University's top innovation executive, responsible for some of Rice’s major innovative projects like the Rice BioTech LaunchPad and Rice Nexus, will leave the university next month to accept a position at the University of Virginia.

Cherukuri, Rice’s first vice president for innovation and chief innovation officer, will become the University of Virginia’s Donna and Richard Tadler University Professor of Entrepreneurship and the school's first chief innovation officer, according to a release from Rice. Cherukuri, who has served for more than 10 years at Rice, plans to depart his current position on Sept. 30.

Adrian Trömel, associate vice president for innovation strategy and investments at Rice, will serve as interim vice president for innovation and chief innovation officer after Cherukuri departs, and as the university starts an international search for his replacement.

“We appointed Paul to build an ambitious and high-functioning innovation operation, and he has succeeded remarkably in short order,” Rice President Reginald DesRoches said in the release. “In every area, from technology translation and startup creation to commercialization and entrepreneurship training, he has led the effort to vastly improve our structure, operations and relationships. He has contributed immensely both to our strategies and their implementation across numerous areas, and we’ll miss him greatly.”

Cherukuri is a physicist, chemist and medical technology entrepreneur, and has been a member of DesRoches’ leadership team since 2022. Cherukuri served as executive director of Rice’s Institute of Biosciences and Bioengineering from 2016 to 2022, where he helped in the development of interdisciplinary translational research partnerships with federal and corporate agencies. His work helped earn nearly $37 million in funding for accelerating the development of new technologies into commercial products. In the energy transition field, Cherukuri led a $12.5 million partnership with Woodside Energy to transform greenhouse gases into advanced nanomaterials for next-generation batteries and transistors.

Initiatives the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion; were all launched under Cherukuri’s leadership. With his work at the Ion, Cherukuri also led the announcement of a partnership with North America’s largest climate tech incubator, Greentown Labs.

“I am proud of the relentless innovative spirit we have built for Rice in Houston and around the world,” Cherukuri said in the release. “I look forward to bringing new energy and vision to UVA’s efforts in this critical space for our country, its success and future.”

From Your Site Articles
Four Rice University lab-stage innovations are receiving fresh funding to get them closer to commercialization. Photo courtesy of Rice University

Rice names inaugural recipients of new grant program that's doling out $360,000

Four Houston research projects are splitting hundreds of thousands of dollars in grant funding from Rice University.

After announcing the One Small Step Grant program in September to support Rice-developed, lab-stage innovations, the university has named its inaugural recipients. After receiving nearly 30 applicants, four research projects were selected to share $360,000 in grant funding.

“Being able to fund near-commercial projects represents a leap forward in our mission of supporting the cutting-edge work of our faculty and students and helping bring those to market,” Adrian Trömel, assistant vice president for strategy and investments, says in a news release. “Feedback from industry and investors show that they’re excited on how the One Small Step grants help derisk these technologies, getting them ready to launch. Watch this space for the next generation of leading deeptech companies.”

The selected projects include:

  • PerisBio, developed by Samira Aglhara Fotovat and Samantha Fleury from Rice Professor Omid Veiseh's Lab, focuses on novel, hydrogel-encapsulated engineered "cell factories" for the minimally invasive treatment of endometriosis. The project received a $100,000 award.
  • Solidec, founded by Ryan Duchanois and Yang Xia from Rice Professor Haotian Wang's Lab, is a room temperature, solid-state direct air capture technology. The project received a $100,000 award.
  • HornetX, led by Rice Professor Aditya Mohite's Lab, aims to produce highly stable green hydrogen using a perovskite-based photoelectrochemical cell with leading efficiency. The project received a $80,000 award.
  • Coflux, developed by Jeremy Daum and Alec Ajnsztajn from the labs of Rice Professors Rafael Verduzco and Pulickel Ajayan, focuses on covalent organic framework-based photocatalysts for instream remediation of PFAS (per- and polyfluoroalkyl substances) from water. The project received a $80,000 award.

The Office of Innovation created an investment advisory committee — made up of entrepreneurs, investors and corporate executives across industries — to select these recipients. The grant program was funded by the Office of Innovation, with support from Breakthrough Energy Fellows for climate and energy projects

“The inaugural winners of the One Small Step Grant represent the innovative spirit and dedication to excellence that defines our students and faculty," Rice Chief Innovation Officer Paul Cherukuri says. "We are proud to support these groundbreaking projects on their journey from lab to market."

Former University of St. Thomas business school dean, Beena George, is taking on a new role at the university: Chief innovation officer. Courtesy of UST

Houston educator plans to lead her university into the future with her new role

Featured innovator

High school graduation numbers are decreasing, and, by 2025, far fewer college freshmen will be starting school. Some project as high as a 15 percent drop, says Beena George, inaugural chief innovation officer of Houston's St. Thomas University.

UST is looking forward to and anticipating changes and challenges within higher education like this, and one of the steps the university has been to create George's position.

"My role is to ferment that culture of innovation," George says. "Not just sit here and think of ideas."

As the school gets ready to welcome students back onto its Montrose campus, the former business dean gets ready to serve in her new role for the first semester. She spoke with InnovationMap about her career, goals, and the role UST plays within the Houston innovation ecosystem.

InnovationMap: What have you learned throughout your career that has prepared you for the role?

Beena George: I've always been interested in solving problems. If I saw something that was an opportunity, and we didn't take advantage of it, I'll keep thinking about it. I've been thinking about what makes me enjoy this role and stage in my career, and I think it's because most roles tend to be mostly operational, but this is thinking of new things and doing things differently and checking your own assumptions. That is what really engages me in my role. My career has given me different opportunities to use this, but not so much as now. When teaching, you have that opportunity every day — engaging students differently. Then as dean, it was about looking at new opportunities and programs for the business school, like our Master of Clinical Translation Management program.

IM: How did this clinical translation program come about?

BG: The idea of clinical translation is essentially to move a discovery from the lab to the patient's bedside — it's the commercialization of life sciences. The program trains students to shepherd a discovery from the lab to the commercial setting so that it's available to patients.It's a combination of business, life sciences, regulatory affairs. It's a one-year online program with some residency periods. It's the only of its kind in Houston and is one of less than 10 in the United States and, to my knowledge, the only of its kind in a business school.

IM: What does innovation mean to the University of St. Thomas and this inaugural position?

BG: I think innovation isn't entirely new on college campuses, but now is a time when higher education is in flux. There has been a lot of changes in the industry and in society in general that's requiring higher education institutions to react in a different way. Some of the things that we've always been doing — creating new programs, moving online, new campuses — now it's even more important to bring that to prominence and figure out how it fits with your university. Things have changed, so the rate at which you're innovating has to increase.

IM: What’s on your to-do list for this first year and within five years?

BG: Since this is a new role, my first goal for the next two to three months is the process of discovery — internally and externally. One of the cool things that's happening in Houston is all these partnerships and collaborations. That's what I'm trying to do — learn about the groups here and outside and make these connections. The other part of it is bringing information in from the outside. There are so many different ways of doing things. For instance, in higher education, it's been historically tied to credit hours. We know now there are many different ways to look at education. That's the kind of conversation I look to get started.

IM: You mention collaboration, and I think that’s key when it comes to higher education institutions within the innovation ecosystem, but how do you see that teamwork affecting the city as a whole?

BG: So I have been so glad to see that, because I've always believed that there has to be some competition — it ensures that everyone performs at their best. But there are some industries where you have to go beyond competition to the next level and manage competition and collaboration at the same time. We have two networks — Texas Medical Center and the academic partnership created by The Ion — and talk about what's happening on your campuses and how we can work together in Houston. There's also the 60x30 Texas, which has different advisory councils that offers that same conversation of collaboration to work together to meet our goals. Those types of conversations are important and having those types of venues to do that can have only a positive effect on Houston.

IM: How is UST finding new ways to prepare its students for the workforce?

BG: One thing that has gained a lot of attention here on campus is providing students with more experiential learning opportunities — more internships and apprenticeships and bringing the industry into the classroom. Carlos Monroy, a professor at UST, and his student worked on a project for the city. This is something that allows us to remain connected to the industry and it gives our faculty the idea of what the Industry needs and they can focus on that in the classroom.

IM: UST recently announced a major “renewal” plan. How is this going to affect innovation efforts on campus?

BG: I think the whole process is about innovation. What we have is an opportunity to recreate ourselves for the next millennium and create a sustainable operating model that will continue to provide for our students. I think it will affect everything.


------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston medtech firm secures $30M for neurosurgical robot

stroke surgery

Robotic neurosurgery is an exciting new frontier in medicine, and Houston-based medtech firm XCath is leading the charge with its revolutionary Iris robotic system. The company announced in March that it had secured $30 million in Series C funding to continue developing systems to tackle blood clots in the human brain.

“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases,” Eduardo Fonseca, CEO of XCath, said in a news release. “In 2025, the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”

XCath–which also has campuses in Pangyo, South Korea–has already achieved a number of remarkable firsts in robotic neurosurgery. The Iris is the only endovascular robotic system currently in development to perform intracranial navigation or neurointerventional treatment, and is the only robot in the world to have performed an intracranial neurovascular procedure involving the robotic manipulation of three devices.

These new Series C funds, which bring the company's total investment to $92 million, will go toward developing a clinical telerobot capable of performing a mechanical thrombectomy. This would bring unprecedented accuracy and precision to the surgical removal of brain clots, significantly reducing the risk of neurosurgery.

“Robotic surgery succeeds when innovation is paired with practical execution,” Dr. Fred Moll, chairman of the XCath board of directors, said in the release. “XCath has built a promising technology foundation, and just as importantly, a team that values rigor and appreciates perspective. I’m excited to support them as they take on the mission of globalizing access to gold-standard care for stroke patients.”

In November 2025, the Iris debuted under the control of Dr. Vitor Mendes Pereira at The Panama Clinic in Panama City, alongside local Principal Investigator Dr. Anastasio Ameijeiras Sibauste. It was only the second time in human history that a robot had been used for intracranial neurovascular intervention, and it established Iris as a viable technology in the fight against stroke.

“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems,” Nicholas Drysdale, CFO of XCath, added in the release. “With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics”.

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

View All Listings